We are live on ! Find out more
ZOM

Zomedica Corp.
ZOM

Delisted

ZOM was delisted on the 4th of March, 2025.

Back to rankings

91 hedge funds and large institutions have $23.5M invested in Zomedica Corp. in 2022 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 17 increasing their positions, 13 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

63% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 8

31% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 13

21% more capital invested

Capital invested by funds: $19.5M → $23.5M (+$4M)

5% more funds holding

Funds holding: 87 → 91 (+4)

Holders
91
Holders Change
+4
Holders Change %
+4.6%
% of All Funds
1.46%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
17
Reduced
13
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$510K
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$46.9K
3
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$36K
4
Morgan Stanley
Morgan Stanley
New York
+$31.6K
5
MCC
Money Concepts Capital
Florida
+$31.2K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$182K
2
VF
Virtu Financial
New York
-$115K
3
Charles Schwab
Charles Schwab
California
-$73K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$46K
5
UBS Group
UBS Group
Switzerland
-$44K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of America
76
Bank of America
North Carolina
$541 +$461 +2,251 +211%
FWM
77
Focused Wealth Management
New York
$416 – – –
KFS
78
Kelly Financial Services
Massachusetts
$245 – – –
AF
79
Advisornet Financial
Minnesota
$244 – – –
SWA
80
SOA Wealth Advisors
New York
$177 – – –
SIC
81
Salem Investment Counselors
North Carolina
$163 – – –
EWA
82
EverSource Wealth Advisors
Alabama
$49 – – –
HCP
83
Hexagon Capital Partners
Arkansas
$46 +$58 +283 New
HPC
84
HM Payson & Co
Maine
$41 – – –
PNC Financial Services Group
85
PNC Financial Services Group
Pennsylvania
$32 +$41 +200 New
HI
86
Harbour Investments
Wisconsin
$23 – – –
Charles Schwab
87
Charles Schwab
California
– -$73K -343,967 Closed
Susquehanna International Group
88
Susquehanna International Group
Pennsylvania
– -$46K -220,286 Closed
UBS Group
89
UBS Group
Switzerland
– -$44K -210,693 Closed
Millennium Management
90
Millennium Management
New York
– -$34K -159,009 Closed
BPA
91
Beacon Pointe Advisors
California
– -$17K -81,911 Closed
RJFSA
92
Raymond James Financial Services Advisors
Florida
– -$3K -15,915 Closed
Citadel Advisors
93
Citadel Advisors
Florida
– -$3K -15,705 Closed
SFCL
94
Strengthening Families & Communities LLC
Massachusetts
– +$2 +9 New
CWM
95
CarsonAllaria Wealth Management
Illinois
– +$4 +20 New
1 2 3
4

ZOM Hedge Fund Activity: Q4 2022 in Review

91 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Zomedica Corp. (ZOM) for Q4 2022, worth a combined $23.5M — up 21% from $19.5M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new ZOM positions and 8 closed out — a net gain of 5 holders — while 17 added to existing stakes and 13 trimmed.

The largest buyer was Vanguard Group, adding an estimated $510K. The largest seller was Renaissance Technologies, cutting an estimated $182K.

  • 91 institutional investors held Zomedica Corp. (ZOM) as of Q4 2022, up from 87 in Q3 2022.
  • Funds reported $23.5M of Zomedica Corp. stock for Q4 2022, up 21% quarter-over-quarter.
  • 13 funds opened new Zomedica Corp. positions in Q4 2022 and 8 closed out, a net change of +5 holders.
  • The largest Zomedica Corp. buyer in Q4 2022 was Vanguard Group, an estimated $510K added.
  • The largest Zomedica Corp. seller in Q4 2022 was Renaissance Technologies, an estimated $182K sold.

Based on aggregated 13F filings for Q4 2022.